REGN 10597
Alternative Names: REGN-10597Latest Information Update: 25 Nov 2024
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 23 Sep 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (IV) (NCT06413680)
- 14 May 2024 Regeneron Pharmaceuticals plans a phase I/IIa trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV) in September 2024 (NCT06413680)
- 26 Jun 2023 REGN 10597 is available for licensing as of 26 Jun 2023. https://www.regeneron.com/about/collaborations (Regeneron Pharmaceuticals website, May 2023)